Journal of Cellular Immunology
ISSN: 2689-2812

Commentary - Journal of Cellular Immunology (2021) Volume 3, Issue 6

Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances

Yilun Deng1, Ryan M Reyes2,3, Chenghao Zhang1,4, José Conejo-Garcia5, Tyler J. Curiel1,2,3,6*

1Discipline of Pharmacology, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa

2Department of Chemistry, University of the Western Cape, Bellville 7535, South Africa

3South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa

4Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa

5South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa

6Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa

*Corresponding Author:
Tyler Curiel
E-mail:curielt@uthscsa.edu

Received date: August 12, 2021; Accepted date: December 04, 2021

Citation: Deng Y, Reyes RM, Zhang C, Conejo-Garcia J, Curiel TJ. Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances. J Cell Immunol. 2021;3(6):387-396.

Copyright: © 2021 Deng Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Keywords

Ovarian cancer, Immunotherapy, IL-2, Regulatory T cell, IL-2 receptor


IL-2 and IL-2 Receptor

Interleukin (IL)-2 was first identified as a potent T cell growth factor in 1976 [1] and cloned in 1983 [2]. In the late 1990s, IL-2 gained further attention as the first immunotherapy demonstrating clinical efficacy against metastatic cancer, as high dose IL-2 was approved by the United States Food & Drug Administration (FDA) for the treatment of metastatic renal cell carcinoma in 1992 and metastatic melanoma in 1998 [3]. However, initial IL-2 immunotherapy treatment regimens led to severe and sometimes fatal toxicity in patients [4], significantly limiting its clinical application. Early treatment regimens were thought to require high doses of IL-2 for several reasons. IL-2 has a short in vivo half-life [5], requiring frequent dosing to maintain its biological effect of stimulating antitumor immunity. There are different forms of the IL-2 receptor (IL-2R) with different affinity for IL-2 [6] that express distinct cellular expression patterns (Figure 1A). Effector T cells (Teffs) and natural killer (NK) cells, linchpins of antitumor immunity, constitutively express intermediate-affinity IL-2Rs at baseline, which are dimeric receptors comprised of IL-2Rβ (CD122) and IL-2Rγ (common γ-chain or CD132) [6] subunits. Yet, a major immunosuppressive population in the tumor microenvironment (TME), regulatory T cells (Tregs) among other populations, express trimeric high-affinity IL-2Rs [6], which consist of IL-2Rβ, IL-2Rγ and IL-2Rα (CD25) subunits (Figure 1A). Therefore, unaltered IL-2 must be used at high doses for optimal Teff activation via intermediate affinity IL- 2Rs as a trimeric IL-2R binds IL-2 with roughly 10-100-fold higher affinity than a dimeric IL-2R [5], rendering Tregs a great competitive advantage for IL-2 availability over Teffs in the TME.

IL-2/anti-IL-2 mAb Complexes

To overcome limitations of native IL-2 in cancer treatment, many engineered forms or complexes of IL-2 have been developed in the past decade [7-21]. These approaches include PEGylated IL-2 agonists [18,19,22,23], IL-2 fusion proteins [12,23], IL-2 and anti-IL2 mAb complexes [7,24- 26], IL-2 with the CD25 binding site genetically deleted [27] and IL-2 fused to CD25 [28] among others [23,29], aiming preferentially activate antitumor effector cells over Tregs, and in some cases also to prolong IL-2 in vivo half-life. These agents are in different stages of preclinical/clinical research, recently reviewed elsewhere [23]. In particular, several groups have designed IL-2 agents that preferentially signal to Teffs through intermediate-affinity IL-2Rs over Tregs, including Boyman and colleagues who described selective activation of immune populations by distinct IL-2/anti-IL-2 immune complexes in 2006 [7]. This group used an anti-IL-2 mAb clone JES6-5H4 (S4B6-like) that could sterically block the interaction between IL-2 and CD25 while conformationally stabilizing the IL-2:CD122 interaction, leading to preferential activation of CD122 expressing (in the intermediate affinity IL-2R) Teffs and NK cells over Tregs [16] (Figure 1B). This CD122-selective IL-2 complex (IL-2c) is the focus of this commentary as several groups have previously shown the efficacy of IL-2c in multiple murine cancer models including B16/F10 melanoma [9,10,30], pancreatic cancer model [8], BCL1 leukemia [9], TRAMP-C1 sarcoma [14], and orthotopic bladder cancer [31].


IL-2c Treats an Immune Checkpoint Blockade Resistant Mouse Ovarian Cancer Model

Recently, we reported beneficial treatment effects of IL- 2c in a mouse ovarian cancer model [32] (major findings summarized in Figure 2), a significant advance in ovarian cancer (OC) immunotherapy for several reasons. OC is the deadliest gynecological cancer, leading to an estimated 13,700 deaths in the United States in 2021 [33]. It should respond to immunotherapies since intratumoral T cell infiltration predicts improved OC patient survival [34] which we showed is reduced by intratumoral Tregs [35]. However, decades of OC immunotherapy trials done by outstanding groups have been largely disappointing [36], which could be in part due to OC’s relatively low mutation burden compared to other tumors [36].

We found IL-2c is highly efficacious in the aggressive and poorly-responsive ID8agg mouse ovarian cancer line that we developed, including being refractory to immune checkpoint blockade (ICB) with α-programmed death ligand 1 (PD-L1). Consistent with known IL-2c effects, IL-2c promoted the activation of effector CD8+ T cells and CD4+ non-Treg cells and increased production of antitumor cytokines including IFNγ and TNFα by these cells in ID8agg challenge. Surprisingly however, IL-2c also expanded the number of Tregs thus reducing the CD8+ T cell/Treg ratio specially in ascites, an effect not previously reported with this approach, which could reflect the OC TME or OC cells themselves. Further investigation revealed that IL-2c treatment impaired Treg suppressive function in a TME-specific manner as Tregs from tumor draining lymph nodes (TDLN) suppressed normally.

Although the half-life of IL-2c is around 24 hours in vivo [11], we observed significant tumor-inhibitory effects as long as three weeks after the last dose of IL-2c. These data suggest induction of immune memory, evident by observed increases in central and effector memory CD8+ T cells after IL-2c treatment. Because IL-2c can increase TILs and tumors with pre-existing T-cell infiltration respond well to ICB [37], we explored combination of IL-2c and αPD-L1 therapy and found a synergistic effect of IL-2c plus αPD-L1 that was superior to either agent alone, in both (no t)ID8agg OC and B16 melanoma model. Moreover, mice that recovered from primary ID8agg challenge after combination therapy were resistant to subsequent tumor challenge, confirming induction of protective immune memory. Thus, IL-2c can work through simultaneous targeting of distinct immune pathways with effects that include: 1) activating effector T cells and promoting their antitumor cytokine production, 2) inhibiting immune-suppressive Tregs, and 3) inducing durable, protective immune memory.

In recent work, we performed additional exploration into the specific immune population(s) responsible for IL-2c efficacy in ID8agg tumors. CD8+ T cells are the primary target populations of IL-2c and are required for successful IL-2c treatment in several tumor models [9,14]. However, we found IL-2c was efficacious in ID8agg tumors following antibody-mediated CD8+ T cell depletion in vivo depletion. We tested two depletion timepoints, during the course of IL-2c treatment starting in week 2 or a week post the last dose of IL-2c (week 3), both of which significantly depleted CD8+ TILs for the duration of the experiment (Figure 3B) and did not affect IL-2c efficacy (Figure 3A). This result was striking because despite IL-2c mediated activation of CD8+ TILs in other models (Table 1), they were dispensable for IL-2c efficacy here. We also recently published that in orthotopic MB49 mouse bladder cancer, CD8 T+ cells were not required for IL-2c efficacy, which instead relied on δ T cells [31]. However, IL-2c treated ID8agg tumors effectively in γδ T cell-deficient mice [31], consistent with TME-specific IL-2c effects.

AuthorYearAgent TestedImmune cell activation invitroImmune cell activation in non- tumor bearing micein vivo efficacyCombination therapyPopulation responsiblefor efficacyImmune change in TMERef
Boyman et al2006IL-2/mAb complexMouse & human Teff proliferation     7
Kamimura et al2006antiIL-2 mAb + IL-2 cDNA Expansion of CD8, NKcells, decrease TregsB16 lung metastasis   24
Verdeil etal2008IL-2/mAb complexMouse & human Teff proliferation, cytokine production pancreatic modelvaccination CD8 expansion, pSTAT5, effector molecule cytokine production8
Jin et al2008IL-2/mAb complex Expansion of DC, NK, CD8 in spleen, increased perforin and GB for NK cellsB16 lung metastasis NK cells required, but not DCs 30
Tomala etal2009IL-2/mAb complex
Both S4B6 and JES6-1 are able to activate CD8 T cells; Only S4B6 activate NK cellsB16 SQ CD8 and NK cells required 9
BCL1 leukemia CD8 required 
Letourneau et al2010IL-2/mAb complex CD8+ t cell proliferation    11
Krieg et al2010IL-2/mAb complex Expansion of CD8, NKand TregsB16 SQ, B16
lung
   10
Redmond et al2012IL-2/mAb complex

MCA-205
sarcoma
OX40
agonistAb
T cells required 14
TRAMP-C1-
mOVA prostate
[doesn't respond to IL-2c alone]Expansion of OT-1 CD8 (ki67,GB, KLRG1)
Cho et al2012IL-2/mAb complex  B16 SQvaccination,
adoptive T cell transfer, aPD-L1
  21
Raeber etal2020IL-2/mAb complexNo cDC actiavation
in vitro
cDC expansion in vivo through IL-2 stimulated ILCsB16 SQ, Braf melanoma B16: DC is requiredExpansion of cDC1 in the tumor25
Drerup et al2020IL-2/mAb complex  ID8agg OC,B16 SQaPD-L1 Activation of tumor CD8+ and CD4+ non-Tregs with increased production
of anti-tumor cytokines. Induce Tregfragility in local TME but not TDLN.
32
Reyes et al2021IL-2/mAb complex  MB49, MBT-2
orthotopic Bladder Cancer, MB49 metastatic lung
aPD-L1MB49: CD8 not
required; gdT cells required
No activation of CD8+ seen inMB49 orthotopic.
Significantly increased intratumoral NK and γδ T cellcontent, activation , and effector function
31
Gillies etal2011NHS-IL2LT IL-2
variant fusion with an antibody (NHS76)
mouse CD8, CD4 (proliferation)
LLC lung cancer CD8 and NK cells required, CD4 not required 12
NXS2
neuroblastoma liver metastasis
   
Levin et al2012IL-2 superkine & IL-2/mAb complexhuman NK cell pSTAT5 status (also in CD25-/-)CD8+ expansionB16 SQ; B16 lung;
MC38,Lewis lung carcinoma
   13
Carmenate et al2013human IL-2 muteinMouse NK, CD8 proliferation but not Tregs
MB16F0
melanoma
lung metastasis
 CD8 and NK cells required 15
3LL-D122 mouse lungcarcinoma   
Charych et al2016Bempegaldesleu kin NKTR-214
(pegylated IL-2)
mouse T cells pSTAT5
B16 SQaCTLA-4 Expansion of CD8, NK, decreased CD4, increased intratumoral CD8/Treg ratio22
EMT6 breast cancer, CT26 colon model   
Charych et al2017Bempegaldesleu kin: NKTR-214
(pegylated IL-2)
 pSTAT5 on CD3+ in PBMBT-2 (bladder), H22(liver), Pan02 (pancreatic)   18
Sockolosky et al2018orthoIL2(CD8, Tregs)pSTAT5,
proliferation
 B16  Increased CD8IFNg production, PD-1 Tim3 expression17
Sun et al2019Ab-sumIL2

B16aPD-L1CD8 required; NK, MDSC, CD4 not
required
Increased CD8/Treg ratio, increased CXCR5+PD-1+ cells,increase PD-L1 on DCs40
MC38   
Sahin et al2020hIL-2/NARA1pSTAT5 comparison Cytotoxic T cells, NK cell, TregspSTAT5, Ki67, cell counts, for CD8, NK and TregsB16 (sQ and metastatic) LLC lung; 4T1breast 4T1: doesn't treat primary as
single agent but reduces metastasis
hIL-2/NARA1: increase CD8, NK1.1, Treg; NARA1leukin: not Treg; lower exhausted Tcells26
Sharma et al2020Bempegaldesleu kin  B16, Colon (CT- 26), ovarian (BR5FVB),
bladder (MBT- 2), liver (H22), pancreatic (Pan02), breast (EMT-6), lung
(LLC),
aPD-1,
vaccine
  19
Hsu et al2021ProIL2  MC38, CT26,B16aPD-L1 Increased CD8, decreased Foxp3, increased ratio29


IL-2c Induces TME Treg Fragility Independent of CD8+ and δ T cells

Tregs are a major immune-suppressive population in the TME and are associated with worse outcomes in OC patients [35]. Tregs also play a crucial role in the development of ID8agg tumors as we previously showed that depleting Tregs completely abolished ID8agg tumor progression [32]. Strikingly, fragile Tregs were first described by the Vignali group and are characterized by maintained FoxP3 expression with loss of suppressive function and decreased production of effector molecules including granzyme B, versus an unstable Treg phenotype where Tregs lose their FoxP3 expression [38]. Fragile Tregs also express transcription factor T-bet and produce cytokines that are uncharacteristic of normal Tregs [39], including IFNγ. Treg fragility can also contribute to ICB treatment efficacy [38,39] which could be another mechanism of IL-2c synergy with αPD-L1. We found that Tregs displayed a fragile phenotype induced by IL-2c, which helps explain IL-2c efficacy despite increasing Treg numbers in the OC TME. We performed t-distributed stochastic neighbor embedding (tSNE) analysis of Tregs in the OC TME and TDLN and found that Tregs in TDLN treated with control or IL-2c have a similar immune phenotype, whereas IL-2c-treated Tregs in the ascites acquired the fragile phenotype (Figure 4). By contrast, IL-2c did not induce Treg fragility in the bladder in MB49 bladder cancer, consistent with TME-specific fragility induction.

We further explored mechanisms for IL-2c-induced Treg fragility. We observed that IL-2c-induced fragility can be detected three weeks after the final dose of IL-2c, but not one week after the final dose [32], and is likely indirect from CD25 signals. Ex vivo treatment of Tregs with IL-2c does not fully recapitulate the in vivo fragile phenotype [32], suggesting IL-2c cooperates with another factor or population in the OC TME to induce Treg fragility, or could work during Treg differentiation, which could account for the long time needed for in vivo fragility induction. IFNγ is a potent Treg fragility inducer [38] and IL-2c promotes IFNγ production in effector T cells. We assessed major IFNγ-producing population effects on Treg fragility induction, including CD8+ T cells and γδ T cells. Antibody-mediated CD8+ T cell depletion did not rescue the Treg fragility phenotype in ascites (Figure 5A), and fragile Tregs with increased T-bet, and IFNγ expression were also present in ascites of γδ T cell deficient mice challenged with ID8agg tumors (Figure 5B) excluding δ T cells and making CD8+ T cells unlikely mediators in IL-2c induced Treg fragility. Future studies will test NK cell, innate lymphoid cell and fragile Treg interferon-γ in IL-2c induced Treg fragility and assess other tumors and TME.

Conclusions and Future Directions

Our published studies [31,32] and new data shown here highlight several important mechanisms that could be unique to the OC TME and serve as important contrasts to other studies using the same IL-2c or similar CD122-biased modified IL-2. First, conventional CD8+ T cells are not required for the treatment efficacy of IL-2c in ID8agg OC, despite IL- 2c-mediated promotion of IL-2 signaling and antitumor cytokines production in intratumoral CD8+ T cells. In this specific TME, IL-2c preferentially activates other immune populations that play a more crucial role than CD8+ T cells in treatment efficacy. Absence of OC TME CD8+ T cells is not seen and thus agents such as αPD-L1 that do activate OC TME CD8+ T cells can synergize with IL-2c as we reported. Other IL-2c activated populations including NK cells or other members of the innate immunity could be preferentially activated over CD8+ T cells or insufficient CD8+ T cells could induce compensatory activation of other cell populations. Understanding the preferential and distinct IL-2 signaling and activation of varied immune populations in specific TMEs and/or tumors is essential for comparing differences in IL-2 targeting agent mechanisms between various tumors and anatomic locations, and to define mechanisms for agents that can cooperate clinically with directed IL-2 agents, which to date is little studied. Second, IL-2c inhibits intratumoral Treg function by inducing a fragile phenotype at least in some tumors and environments. CD122-selective IL-2 agents are expected to avoid activation and proliferation of Tregs and most previous studies in other models observed an increased CD8+ T cell/Treg ratio [8,14,22,40] and sometimes even Treg depletion [19]. However, we found increased number of Tregs and fragility in ascites after IL-2c treatment. Studies are warranted to identify fragility mediators, define in what other cancer models or human cancers fragile Tregs can be induced and to understand which agents best combine with this effect for treatment efficacy.

Currently, many modified IL-2 agents are in varied stages of preclinical and clinical development [23] (and Table 1), yet a detailed understanding of the immune landscape during treatment is lacking in most cases. Our prior and ongoing investigations have uncovered unexpected yet useful immune consequences of IL-2c signaling in the OC TME, stressing the importance of understanding the biology and immunology of distinct IL-2 agents to advance our understanding of IL-2 and IL-2 receptor biology, and optimal therapeutic uses. We also shed light on OC-specific TME phenotypes that potentially help explain its unresponsiveness to current immunotherapies, which should facilitate further design of targeted immunotherapies for OC patients.


Funding

YD (CPRIT Research Training Award (RP170345) and Ovarian Cancer Research Alliance Ann and Sol Schreiber Mentored Investigator Award), R. Reyes (NIH T32GM113896, NIH/NCATS TL1 TR002647, NIA T32 AG 021890), T. Curiel (CA054174, CA205965, CDMRP, The Owens Foundation, The Skinner endowment, The Barker endowment, P30 CA054174) and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002645.


Conflict of Interest Statement

All authors declared no conflict of interest.


References